2-amino-9-[3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-7-prop-2-enyl-3H-purine-6,8-dione

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-amino-9-[3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-7-prop-2-enyl-3H-purine-6,8-dione
• 英文别名: 2-amino-9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-1H-purine-6,8-dione
• 化学式: C₁₃H₁₇N₅O₆
• 分子量: 339.3
• InChiKey: VDCRFBBZFHHYGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  161
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• Drug delivery compositions and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10435469B2

  公开（公告）日：2019-10-08

  Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.

  本文提供了用于治疗和/或预防癌症和转移性肿瘤的给药组合物和装置。例如，提供了一种药物输送装置，它包括一种可生物降解的支架，其中携带一种或多种激活先天性免疫系统（如 STING 激动剂）和/或适应性免疫系统（如抗 PD-1 抗体）的抗癌治疗剂。组合物和装置可包括细胞因子（如 IL-15 超拮抗剂）。该给药装置可植入切除肿瘤的空隙中，以防止肿瘤再生和肿瘤转移。此外，还提供了制造给药组合物和装置的方法，以及含有提供组合物和装置的材料的试剂盒。
• [EN] ANTI-TUMOR VACCINE MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] MOLÉCULE VACCINALE ANTITUMORALE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种抗肿瘤疫苗分子及其制备方法和应用
  申请人：UNIV CENTRAL CHINA NORMAL

  公开号：WO2021110120A1

  公开（公告）日：2021-06-10

  一种抗肿瘤疫苗分子及其制备方法和应用。所述抗肿瘤疫苗分子具有式(I)所示结构，在所述式(I)中，A为佐剂，B为抗原，且m个所述A分别通过共价连接臂与所述蛋白共价连接，以及n个所述B分别通过共价连接臂与所述蛋白共价连接。所述抗肿瘤疫苗是新的抗肿瘤分子，免疫性能好，能够产生较高滴度的IgG抗体和较强的细胞免疫能力，热稳定性好，易于保存和运输。 A m-蛋白-B n式(I)
• PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY
  申请人：Technische Universitat Dresden

  公开号：US20170189522A1

  公开（公告）日：2017-07-06

  The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75 NTR , which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75 NTR signalling selected from a p75 NTR antagonist or p75 NTR agonist and at least one TLR receptor agonist selected from an agonist of TLR7 and/or TLR9. The invention further relates to the use of a combination of antagonists and agonists of p75 NTR signalling and agonists of TLR7 and/or TLR9 as vaccine adjuvants and the invention provides vaccine compositions comprising antagonists and agonists of p75 NTR signalling and agonists of TLR7 and/or TLR9. The agonists and antagonists of p75 NTR signalling are useful in the manufacture of drugs for controlling cytokine function, antigen presentation, activation and proliferation of lymphocytes, which is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders, growth disorders, infections and any other conditions involving p75 NTR signal transduction. The invention provides assays to screen for a range of agonists and antagonists of p75 NTR useful in modulating cytokine function, activation and proliferation of lymphocytes. The present invention further provides, therefore, screening assays for agonists and antagonists of p75NTR-modulated immune responses.
• DRUG DELIVERY COMPOSITIONS AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20190153098A1

  公开（公告）日：2019-05-23

  Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.
• SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
  申请人：Children's Hospital of Eastern Ontario Research Institute Inc.

  公开号：US20200384103A1

  公开（公告）日：2020-12-10

  The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.